342 related articles for article (PubMed ID: 27716741)
21. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Shide K; Kameda T; Yamaji T; Sekine M; Inada N; Kamiunten A; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Shimoda H; Kitanaka A; Honda A; Sawaguchi A; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hasuike S; Yamamoto S; Nagata K; Shimoda K
Leukemia; 2017 May; 31(5):1136-1144. PubMed ID: 27807369
[TBL] [Abstract][Full Text] [Related]
22. High resolution melting analysis: a rapid and accurate method to detect CALR mutations.
Bilbao-Sieyro C; Santana G; Moreno M; Torres L; Santana-Lopez G; Rodriguez-Medina C; Perera M; Bellosillo B; de la Iglesia S; Molero T; Gomez-Casares MT
PLoS One; 2014; 9(7):e103511. PubMed ID: 25068507
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
24. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
[TBL] [Abstract][Full Text] [Related]
25. Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.
Balligand T; Achouri Y; Pecquet C; Gaudray G; Colau D; Hug E; Rahmani Y; Stroobant V; Plo I; Vainchenker W; Kralovics R; Van den Eynde BJ; Defour JP; Constantinescu SN
Leukemia; 2020 Feb; 34(2):510-521. PubMed ID: 31471561
[TBL] [Abstract][Full Text] [Related]
26. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
27. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
28. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
29. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
[TBL] [Abstract][Full Text] [Related]
30. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
[TBL] [Abstract][Full Text] [Related]
31. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.
Li N; Yao QM; Gale RP; Li JL; Li LD; Zhao XS; Jiang H; Jiang Q; Jiang B; Shi HX; Chen SS; Liu KY; Huang XJ; Ruan GR
Leuk Res; 2015 May; 39(5):510-4. PubMed ID: 25746303
[TBL] [Abstract][Full Text] [Related]
32. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
33. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
34. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W; Kralovics R
Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
[TBL] [Abstract][Full Text] [Related]
35. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
Edahiro Y; Araki M; Komatsu N
Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
[TBL] [Abstract][Full Text] [Related]
36. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
37. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
38. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
39. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Helbig G
Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
[TBL] [Abstract][Full Text] [Related]
40. Genetic-pathologic characterization of myeloproliferative neoplasms.
Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M
Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]